The Pharma Letter14 小时
Ipsen’s Iqirvo approved in Europe
The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...
Akero Therapeutics: Good Candidate For The MASH Basket
Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...
Ipsen Pharma: Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new ...
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for ...
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for ...
Science Daily4 天
Researchers identify potential new strategy to slow the development of liver fibrosis
A study reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic ...
News Medical on MSN4 天
Activation of PPARβ/δ-AMPK pathway shown to slow liver fibrosis development
A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical ...
Too Old to Operate5 天
Erythropoietin regulates osteoclast formation via up-regulating PPARγ expression.
Erythropoietin (EPO), expressed in red blood progenitor cells, primarily regulates erythropoiesis by binding to its receptor. Besides anemia, recent studies have identified new therapeutic indications ...